| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| SOXC Transcription Factors | 4 | 2014 | 53 | 1.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2014 | 2796 | 0.630 |
Why?
|
| Leukemia, Myelomonocytic, Acute | 2 | 2007 | 72 | 0.530 |
Why?
|
| Transcription Factor 7-Like 1 Protein | 1 | 2014 | 31 | 0.500 |
Why?
|
| Chromosomes, Human, Pair 16 | 2 | 2007 | 254 | 0.480 |
Why?
|
| Wnt Signaling Pathway | 2 | 2014 | 430 | 0.460 |
Why?
|
| Homeodomain Proteins | 2 | 2019 | 1143 | 0.450 |
Why?
|
| B-Lymphocytes | 3 | 2014 | 1294 | 0.440 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2014 | 1094 | 0.410 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2014 | 703 | 0.390 |
Why?
|
| Biopsy, Fine-Needle | 6 | 2020 | 690 | 0.370 |
Why?
|
| Gene Expression Regulation, Leukemic | 3 | 2020 | 560 | 0.340 |
Why?
|
| Immunohistochemistry | 11 | 2020 | 7548 | 0.300 |
Why?
|
| Immunophenotyping | 4 | 2014 | 1681 | 0.300 |
Why?
|
| Receptors, Cytokine | 1 | 2008 | 176 | 0.300 |
Why?
|
| Dendritic Cells, Follicular | 2 | 2005 | 38 | 0.300 |
Why?
|
| Chromosome Inversion | 2 | 2007 | 182 | 0.290 |
Why?
|
| Leukemia, Hairy Cell | 2 | 2004 | 115 | 0.290 |
Why?
|
| Myelolipoma | 1 | 2006 | 12 | 0.280 |
Why?
|
| Lumbosacral Region | 1 | 2006 | 49 | 0.280 |
Why?
|
| Hyaluronan Receptors | 2 | 2005 | 249 | 0.260 |
Why?
|
| DNA-Binding Proteins | 4 | 2014 | 4821 | 0.250 |
Why?
|
| Cell Differentiation | 2 | 2014 | 4078 | 0.240 |
Why?
|
| Paraproteinemias | 1 | 2004 | 61 | 0.240 |
Why?
|
| Flow Cytometry | 4 | 2014 | 3033 | 0.240 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2007 | 2508 | 0.230 |
Why?
|
| Cadherins | 2 | 2005 | 660 | 0.220 |
Why?
|
| Castleman Disease | 1 | 2003 | 69 | 0.220 |
Why?
|
| Apoptosis | 9 | 2013 | 7591 | 0.220 |
Why?
|
| Muscle, Smooth | 1 | 2003 | 236 | 0.210 |
Why?
|
| Organ Transplantation | 1 | 2004 | 191 | 0.200 |
Why?
|
| Cell Division | 2 | 2003 | 2489 | 0.190 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 3203 | 0.190 |
Why?
|
| Lymphoma, Follicular | 2 | 2003 | 587 | 0.190 |
Why?
|
| Biomarkers, Tumor | 9 | 2020 | 10331 | 0.190 |
Why?
|
| Synaptophysin | 1 | 2020 | 79 | 0.190 |
Why?
|
| Carcinoid Tumor | 1 | 2002 | 280 | 0.190 |
Why?
|
| Chromogranin A | 1 | 2020 | 65 | 0.190 |
Why?
|
| Breast Neoplasms, Male | 1 | 2002 | 229 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 5159 | 0.180 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2018 | 509 | 0.180 |
Why?
|
| Immunoglobulins | 1 | 2020 | 266 | 0.170 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 698 | 0.170 |
Why?
|
| DNA Barcoding, Taxonomic | 1 | 2019 | 21 | 0.170 |
Why?
|
| Neovascularization, Pathologic | 2 | 2005 | 1547 | 0.170 |
Why?
|
| Immunoenzyme Techniques | 5 | 2014 | 1165 | 0.170 |
Why?
|
| Genes, BRCA1 | 1 | 2002 | 387 | 0.170 |
Why?
|
| Gene Rearrangement | 2 | 2013 | 783 | 0.170 |
Why?
|
| Indoles | 2 | 2015 | 1009 | 0.170 |
Why?
|
| Cytokines | 1 | 2008 | 2809 | 0.170 |
Why?
|
| BRCA1 Protein | 1 | 2002 | 493 | 0.170 |
Why?
|
| Testis | 1 | 2003 | 717 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2020 | 1664 | 0.160 |
Why?
|
| Multiple Myeloma | 2 | 2014 | 2138 | 0.160 |
Why?
|
| Mutation Rate | 1 | 2019 | 223 | 0.160 |
Why?
|
| Sarcoma | 3 | 2005 | 1725 | 0.150 |
Why?
|
| Carcinoma, Small Cell | 1 | 2019 | 408 | 0.140 |
Why?
|
| Transcription Factors | 4 | 2019 | 5270 | 0.140 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2003 | 882 | 0.140 |
Why?
|
| Middle Aged | 20 | 2020 | 86204 | 0.140 |
Why?
|
| Somatic Hypermutation, Immunoglobulin | 2 | 2013 | 47 | 0.140 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 14551 | 0.140 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2018 | 1216 | 0.140 |
Why?
|
| Janus Kinase 2 | 2 | 2010 | 679 | 0.130 |
Why?
|
| Humans | 39 | 2020 | 261506 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2008 | 2390 | 0.130 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2020 | 406 | 0.130 |
Why?
|
| Immunoglobulin Variable Region | 2 | 2013 | 173 | 0.130 |
Why?
|
| Cell Cycle | 2 | 2013 | 2084 | 0.130 |
Why?
|
| Arylsulfotransferase | 1 | 2015 | 18 | 0.130 |
Why?
|
| ErbB Receptors | 1 | 2003 | 2295 | 0.130 |
Why?
|
| Male | 19 | 2020 | 123000 | 0.120 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2013 | 5 | 0.120 |
Why?
|
| Carcinoma, Lobular | 1 | 2018 | 611 | 0.120 |
Why?
|
| Aged | 16 | 2020 | 70117 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 1 | 2020 | 634 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2010 | 2527 | 0.120 |
Why?
|
| Mice | 9 | 2014 | 34495 | 0.120 |
Why?
|
| Lymphoma, B-Cell | 2 | 2014 | 895 | 0.110 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2013 | 35 | 0.110 |
Why?
|
| Prodrugs | 1 | 2014 | 217 | 0.110 |
Why?
|
| Immunoglobulin gamma-Chains | 1 | 2012 | 11 | 0.110 |
Why?
|
| Female | 22 | 2020 | 141928 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2012 | 8873 | 0.110 |
Why?
|
| Bone Marrow | 2 | 2013 | 2358 | 0.110 |
Why?
|
| Carcinoma | 3 | 2005 | 2578 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2013 | 269 | 0.100 |
Why?
|
| History, 21st Century | 1 | 2014 | 441 | 0.100 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2013 | 146 | 0.100 |
Why?
|
| Leukemia, Myeloid, Acute | 3 | 2020 | 6915 | 0.100 |
Why?
|
| Adult | 14 | 2020 | 77950 | 0.100 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1053 | 0.100 |
Why?
|
| History, 20th Century | 1 | 2014 | 574 | 0.100 |
Why?
|
| Receptor, Notch1 | 1 | 2012 | 218 | 0.100 |
Why?
|
| B7-H1 Antigen | 1 | 2018 | 1022 | 0.100 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 255 | 0.100 |
Why?
|
| Signal Transduction | 5 | 2013 | 11965 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 2359 | 0.090 |
Why?
|
| SEER Program | 1 | 2014 | 1000 | 0.090 |
Why?
|
| Lymph Nodes | 3 | 2014 | 2967 | 0.090 |
Why?
|
| Prognosis | 7 | 2020 | 21713 | 0.090 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2003 | 2979 | 0.090 |
Why?
|
| Aged, 80 and over | 8 | 2020 | 29902 | 0.090 |
Why?
|
| RNA Interference | 1 | 2014 | 1408 | 0.090 |
Why?
|
| Animals | 9 | 2014 | 59536 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2019 | 2291 | 0.090 |
Why?
|
| Hematopoietic Stem Cells | 2 | 2013 | 1242 | 0.090 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 305 | 0.090 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2009 | 54 | 0.090 |
Why?
|
| Neoplasm Metastasis | 1 | 2019 | 5112 | 0.080 |
Why?
|
| Disease Progression | 2 | 2014 | 6682 | 0.080 |
Why?
|
| beta Catenin | 1 | 2013 | 688 | 0.080 |
Why?
|
| Protein Phosphatase 2 | 1 | 2009 | 88 | 0.080 |
Why?
|
| Immunoglobulin M | 2 | 2013 | 347 | 0.080 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2014 | 713 | 0.080 |
Why?
|
| Postoperative Complications | 1 | 2004 | 5542 | 0.080 |
Why?
|
| Mice, SCID | 1 | 2013 | 1869 | 0.080 |
Why?
|
| Chemokine CCL11 | 1 | 2008 | 18 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2014 | 1987 | 0.080 |
Why?
|
| Cell Proliferation | 5 | 2014 | 7226 | 0.080 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 1870 | 0.070 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2009 | 347 | 0.070 |
Why?
|
| Mice, Knockout | 2 | 2014 | 5710 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2014 | 6150 | 0.070 |
Why?
|
| Estrogen Receptor alpha | 1 | 2012 | 701 | 0.070 |
Why?
|
| Piperazines | 3 | 2013 | 2101 | 0.070 |
Why?
|
| Transcription Factor RelA | 1 | 2007 | 184 | 0.070 |
Why?
|
| Cytarabine | 1 | 2013 | 1973 | 0.070 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 4143 | 0.070 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2009 | 362 | 0.070 |
Why?
|
| src-Family Kinases | 1 | 2009 | 478 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2013 | 6100 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2014 | 3154 | 0.070 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2015 | 1217 | 0.070 |
Why?
|
| Pyrimidines | 4 | 2013 | 3518 | 0.070 |
Why?
|
| Liver | 2 | 2013 | 2961 | 0.060 |
Why?
|
| Proteomics | 2 | 2012 | 1380 | 0.060 |
Why?
|
| Cytodiagnosis | 1 | 2006 | 220 | 0.060 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 7789 | 0.060 |
Why?
|
| Incidence | 1 | 2014 | 5673 | 0.060 |
Why?
|
| Interleukin-6 | 1 | 2008 | 1038 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2015 | 3536 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 2003 | 181 | 0.060 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2003 | 27 | 0.060 |
Why?
|
| Child, Preschool | 3 | 2014 | 16273 | 0.060 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2003 | 448 | 0.060 |
Why?
|
| Lymphocytosis | 1 | 2003 | 58 | 0.050 |
Why?
|
| Adolescent | 4 | 2014 | 31252 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2015 | 566 | 0.050 |
Why?
|
| Rhabdomyoma | 1 | 2002 | 23 | 0.050 |
Why?
|
| Tissue Fixation | 1 | 2003 | 136 | 0.050 |
Why?
|
| Mutation | 2 | 2020 | 15179 | 0.050 |
Why?
|
| Prostatic Neoplasms | 1 | 2019 | 5767 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2003 | 272 | 0.050 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2002 | 64 | 0.050 |
Why?
|
| Imatinib Mesylate | 3 | 2013 | 1665 | 0.050 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2007 | 755 | 0.050 |
Why?
|
| Cell Survival | 3 | 2015 | 3045 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2006 | 4744 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2004 | 829 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 14289 | 0.050 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 591 | 0.050 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 14889 | 0.050 |
Why?
|
| Vaginal Neoplasms | 1 | 2002 | 152 | 0.050 |
Why?
|
| Hyperplasia | 1 | 2003 | 557 | 0.050 |
Why?
|
| Ki-67 Antigen | 1 | 2003 | 666 | 0.050 |
Why?
|
| RNA, Viral | 1 | 2004 | 671 | 0.050 |
Why?
|
| Infant, Newborn | 1 | 2014 | 8223 | 0.050 |
Why?
|
| Benzamides | 3 | 2013 | 1832 | 0.050 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2020 | 36 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2006 | 1234 | 0.050 |
Why?
|
| Mesothelioma | 1 | 2005 | 544 | 0.050 |
Why?
|
| Infant | 2 | 2014 | 13310 | 0.040 |
Why?
|
| Herpesvirus 4, Human | 1 | 2004 | 966 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2008 | 5637 | 0.040 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2019 | 49 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2003 | 943 | 0.040 |
Why?
|
| Limit of Detection | 1 | 2019 | 78 | 0.040 |
Why?
|
| Monocytes | 2 | 2013 | 788 | 0.040 |
Why?
|
| Patient Outcome Assessment | 1 | 2020 | 245 | 0.040 |
Why?
|
| Peritoneal Neoplasms | 1 | 2005 | 821 | 0.040 |
Why?
|
| Neutrophils | 2 | 2013 | 835 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2009 | 5178 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2018 | 9180 | 0.040 |
Why?
|
| Child | 3 | 2014 | 29154 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2003 | 2232 | 0.040 |
Why?
|
| Transfection | 2 | 2015 | 2944 | 0.040 |
Why?
|
| Liver Neoplasms | 2 | 2005 | 4557 | 0.040 |
Why?
|
| Translocation, Genetic | 1 | 2003 | 1245 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 11538 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2003 | 2450 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 1183 | 0.040 |
Why?
|
| United States | 1 | 2014 | 15433 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 2330 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2018 | 760 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2014 | 4307 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 2 | 2013 | 5395 | 0.030 |
Why?
|
| Down-Regulation | 2 | 2012 | 2074 | 0.030 |
Why?
|
| Retrospective Studies | 5 | 2020 | 37905 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Disease Management | 1 | 2020 | 1052 | 0.030 |
Why?
|
| Drug Stability | 1 | 2014 | 105 | 0.030 |
Why?
|
| Breast Neoplasms | 2 | 2012 | 15694 | 0.030 |
Why?
|
| bcl-Associated Death Protein | 1 | 2013 | 26 | 0.030 |
Why?
|
| Molecular Structure | 1 | 2014 | 515 | 0.030 |
Why?
|
| Healthy Volunteers | 1 | 2013 | 187 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2003 | 1664 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2006 | 7551 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2014 | 875 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2013 | 247 | 0.030 |
Why?
|
| Proto-Oncogene Proteins pp60(c-src) | 1 | 2013 | 96 | 0.030 |
Why?
|
| Structure-Activity Relationship | 1 | 2014 | 931 | 0.030 |
Why?
|
| M Phase Cell Cycle Checkpoints | 1 | 2012 | 29 | 0.030 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2012 | 76 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2010 | 4804 | 0.030 |
Why?
|
| Polycomb-Group Proteins | 1 | 2011 | 42 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 486 | 0.020 |
Why?
|
| Integrases | 1 | 2013 | 262 | 0.020 |
Why?
|
| Transgenes | 1 | 2013 | 557 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2013 | 479 | 0.020 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2012 | 301 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 2 | 2012 | 3981 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 997 | 0.020 |
Why?
|
| Karyotyping | 1 | 2012 | 1022 | 0.020 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2011 | 160 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2003 | 2326 | 0.020 |
Why?
|
| DNA Primers | 1 | 2012 | 1399 | 0.020 |
Why?
|
| Microarray Analysis | 1 | 2011 | 392 | 0.020 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2011 | 245 | 0.020 |
Why?
|
| STAT5 Transcription Factor | 1 | 2010 | 214 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 2314 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2011 | 32848 | 0.020 |
Why?
|
| Young Adult | 3 | 2013 | 21445 | 0.020 |
Why?
|
| Cyclohexanes | 1 | 2009 | 38 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 7702 | 0.020 |
Why?
|
| Tyrosine | 1 | 2010 | 498 | 0.020 |
Why?
|
| Histone Chaperones | 1 | 2009 | 32 | 0.020 |
Why?
|
| Fetus | 1 | 2013 | 601 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 6009 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2012 | 1489 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2003 | 3022 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 1077 | 0.020 |
Why?
|
| Tyrphostins | 1 | 2009 | 107 | 0.020 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 13658 | 0.020 |
Why?
|
| Estrogens | 1 | 2012 | 751 | 0.020 |
Why?
|
| Time Factors | 1 | 2002 | 12926 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 4053 | 0.020 |
Why?
|
| Neoplasms | 1 | 2013 | 15193 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 3639 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 4938 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2012 | 4233 | 0.020 |
Why?
|
| Base Sequence | 1 | 2012 | 4917 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 3438 | 0.020 |
Why?
|
| Skin Neoplasms | 1 | 2002 | 4654 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2013 | 4757 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2005 | 252 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2012 | 6089 | 0.020 |
Why?
|
| Paclitaxel | 1 | 2012 | 1996 | 0.020 |
Why?
|
| Giant Cells | 1 | 2005 | 69 | 0.020 |
Why?
|
| Mastectomy | 1 | 2011 | 1534 | 0.020 |
Why?
|
| Cell Movement | 1 | 2012 | 2466 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2010 | 1439 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 1678 | 0.020 |
Why?
|
| Interphase | 1 | 2003 | 145 | 0.010 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2012 | 3821 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2011 | 3890 | 0.010 |
Why?
|
| Epithelium | 1 | 2005 | 720 | 0.010 |
Why?
|
| Ascitic Fluid | 1 | 2003 | 76 | 0.010 |
Why?
|
| Paraffin Embedding | 1 | 2003 | 226 | 0.010 |
Why?
|
| Perineum | 1 | 2002 | 107 | 0.010 |
Why?
|
| Pericardial Effusion | 1 | 2003 | 118 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 2005 | 577 | 0.010 |
Why?
|
| Specimen Handling | 1 | 2003 | 299 | 0.010 |
Why?
|
| Sulfonamides | 1 | 2010 | 1823 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 2054 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2003 | 429 | 0.010 |
Why?
|
| Pleural Effusion | 1 | 2003 | 201 | 0.010 |
Why?
|
| Postmenopause | 1 | 2002 | 378 | 0.010 |
Why?
|
| Diagnostic Errors | 1 | 2005 | 509 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2011 | 9244 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2012 | 2947 | 0.010 |
Why?
|
| Neoadjuvant Therapy | 1 | 2011 | 4975 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2005 | 1818 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 1620 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2002 | 1863 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2005 | 4844 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 4971 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 15862 | 0.010 |
Why?
|